Boehringer Ingelheim Corporation (Boehringer)

Oncology Corporate Profile

HQ Location

900 Ridgebury Road
Ridgefield, CT 6877

Company Description

Boehringer Ingelheim is a research-driven group of companies dedicated to researching, developing, manufacturing and marketing pharmaceuticals that improve health and quality of life. Boehringer Ingelheim's research and development focuses on angiogenesis inhibition, signal transduction and cell-cycle kinase inhibition.


Brand Generic Indication
Gilotrif®afatinibGilotrif® is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA - approved test. Safety and efficacy of GILOTRIF have not been established in patients whose tumors have other EGFR mutations.
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
volasertibPLK-1 antagonistAcute Myelogenous Leukemia (AML)III
nintedanibmultiple tyrosine kinase inhibitor (VEGFR, FGFR, PDGFR)Colorectal cancerIII
nintedanibmultiple tyrosine kinase inhibitor (VEGFR, FGFR, PDGFR)MesotheliomaIII
nintedanibmultiple tyrosine kinase inhibitor (VEGFR, FGFR, PDGFR)Non Small Cell Lung Cancer (NSCLC)III
nintedanibmultiple tyrosine kinase inhibitor (VEGFR, FGFR, PDGFR)Ovarian cancerIII
Gilotrif® / afatinib / BIBW 2992EGFR/HER2 inhibitor1st line metastatic Breast cancerIII
Gilotrif® / afatinib / BIBW 2992EGFR/HER2 inhibitorHead & Neck cancerIII
Vargatef® / BIBF 1120multiple tyrosine kinase inhibitor (VEGFR, FGFR, PDGFR)Non Small Cell Lung Cancer (NSCLC)III
Vargatef® / BIBF 1120multiple tyrosine kinase inhibitor (VEGFR, FGFR, PDGFR)Ovarian cancerIII
BI 811283serine/threonine kinase Aurora BAcute Myelogenous Leukemia (AML)II
volasertib / BI 6727polo-like kinase 1 (PLK1) inhibitorNewly diagnosed Acute Myelogenous Leukemia (AML)II
BI 6727PLK-1 inhibitorVarious cancer typesII
Vargatef® / BIBF 1120multiple tyrosine kinase inhibitor (VEGFR, FGFR, PDGFR)MesotheliomaII
BI 836858serine/threonine kinase Aurora BMyelodysplastic Syndrome (MDS)I
HM61713EGFR inhibitorNon Small Cell Lung Cancer (NSCLC)IHammi
Gilotrif® / afatinib / BIBW 2992EGFR/HER2 inhibitorGlioblastoma Multiforme (GBM)I
volasertib / BI 6727polo-like kinase 1 (PLK1) inhibitorLeukemiaPreclinical

View additional information on product candidates here »


Recent News Headlines

Boehringer Ingelheim and Sarah Cannon Research Institute Launch Strategic Collaboration to Develop Novel Immune-Oncology Therapies

9/29/2016 05:29 pm

(Boehringer Ingelheim) Sept 29, 2016 - Boehringer Ingelheim and Sarah Cannon Research Institute, the research arm of Sarah Cannon, the global cancer institute of HCA, announced today a new strategic collaboration. This partnership brings together Boehringer Ingelheim's extensive experience in cancer drug development and Sarah Cannon's expertise and leadership in designing and optimizing clinical trials. The partnership will help bring innovative cancer treatments to patients with unmet medical needs.

Amgen Obtains Global Development And Commercial Rights From Boehringer Ingelheim For Investigational BiTE® Immuno-Oncology Drug For Multiple Myeloma

9/1/2016 04:13 pm

(Amgen) Sept 1, 2016 - Amgen and Boehringer Ingelheim today announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908 (AMG 420), a bispecific T cell engager (BiTE®) that targets B-cell maturation antigen (BCMA), a potential target for multiple myeloma.

CANbridge Signs Agreement with Boehringer Ingelheim to Manufacture Inhibitory Antibody, CAN-017, for Esophageal Squamous Cell Cancer

8/12/2016 04:18 pm

(CANbridge Life Sciences) Aug 11, 2016 - Boehringer Ingelheim and CANbridge Life Sciences announced that both parties have signed an agreement for the manufacture of CAN-017, an ErbB3 (HER3) inhibitory antibody to treat esophageal squamous cell cancer (ESCC), CANbridge plans to initiate a Phase IIa clinical trial for the treatment of ESCC in Greater China.

Sanofi Gains EU Approval for Boehringer Consumer Health Unit Buy

8/4/2016 04:19 pm

(Reuters) Aug 4, 2016 - French drugmaker Sanofi secured EU antitrust approval on Thursday for its proposed buy of German peer Boehringer Ingelheim's consumer health business after agreeing to divest businesses from both companies in nine EU countries.

Boehringer Stops Gilotrif Trials

7/26/2016 04:07 pm

(PharmaTimes [UK]) July 26, 2016 - Boehringer Ingelheim has stopped two phase III trials for its successful lung cancer drug Gilotrif (afatinib) on the advice of a data monitoring committee.

Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer

7/13/2016 03:38 pm

(Lilly) July 13, 2016 - Eli Lilly and Company and Boehringer Ingelheim today announced a new collaboration on a Phase 1b study that will evaluate the safety and tolerability of abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, in combination with BI 836845, Boehringer Ingelheim's insulin-like growth factor (IGF)-1/IGF-2 ligand neutralizing antibody, in patients diagnosed with HR+, HER2- mBC.

New Data On Olmutinib (BI 1482694) Presented at ASCO 2016 Underscores Clinical Potential Of Boehringer Ingelheim's Next Generation Lung Cancer Compound

6/5/2016 11:17 pm

(Digital Journal) June 5, 2016 - Promising efficacy and safety profile of olmutinib (BI 1482694) is reaffirmed by further clinical data presented at ASCO 2016 annual meeting.

Boehringer Ingelheim Launches Ambitious Eluxa Trial Programme To Broadly Investigate Promising Lung Cancer Compound Olmutinib

6/3/2016 06:21 pm

(Boehringer Ingelheim) June 2, 2016 - Boehringer Ingelheim has initiated the ELUXA trial programme, designed to further investigate the therapeutic potential of olmutinib (BI 1482694 / HM61713), a novel third-generation, epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI) for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC).

Celator Gets Bought, Seeing Stock Rocket from $1.68 to $30.25 in Two Months

5/31/2016 10:05 am

(Forbes) May 31, 2016 - Two months ago, hardly anyone thought much of Celator Pharmaceuticals. The cancer drug developer’s stock was trading for less than $2 a share on thin volumes.

A Better Way to Diagnose and Manage Neuroendocrine Tumors

5/11/2016 11:03 am

(SNMMI) May 9, 2016 - A recent study reported in the May issue of the Journal of Nuclear Medicine demonstrates that Ga-68 DOTATATE PET/CT scans are superior to In-111 pentetreotide scans, the current imaging standard in the United States for detecting neuroendocrine tumors (NETS), and could significantly impact treatment management.

FDA Panel Urges Mandatory Opioid Training for Doctors

5/5/2016 11:05 am

(Wall Street Journal) May 4, 2016 - An advisory panel to the Food and Drug Administration overwhelmingly endorsed mandatory training for doctors who prescribe opioid painkillers, in an effort to stem what has become a national epidemic of deaths and addiction from the drugs.

Califf: FDA Can't Isolate Itself From Industry, Despite 'Touchy' Issues

4/20/2016 12:03 pm

(STAT) Apr 19, 2016 - The new Food and Drug Administration chief says the agency has to work with industry groups so it can keep up with the latest developments in medical science — because otherwise, even the agency’s best experts will fall behind.

US Widens Use Of Boehringer's Lung Cancer Drug Gilotrif

4/18/2016 05:33 pm

(PharmaTimes [UK]) Apr 17, 2016 - US health officials have expanded the approved indications for Boehringer Ingelheim’s Gilotrif, clearing its use in patients with squamous cell carcinoma of the lung.

Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Classical Hodgkin Lymphoma (cHL)

4/18/2016 11:03 am

(Morningstar) Apr 18, 2016 - Fourth Designation for KEYTRUDA follows breakthrough status in advanced melanoma, non-small cell lung cancer, and colorectal cancer.

Boehringer's Giotrif Beats AZ' Iressa In Lung Cancer Trial

4/13/2016 05:20 pm

(PharmaTimes [UK]) Apr 13, 2016 - Boehringer Ingelheim’s Giotrif has beaten AstraZeneca’s Iressa on a number of clinical measures investigated in a head-to-head study involving patients with EGFR mutation-positive advanced non-small cell lung cancer.

ARIAD Announces Initiation of Randomized, First-Line Phase 3 Trial of Brigatinib in Treatment of ALK-Positive Non-Small Cell Lung Cancer

4/11/2016 11:01 am

(ARIAD Pharmaceuticals) Apr 11, 2016 - ARIAD Pharmaceuticals, Inc. today announced the initiation of a randomized, first-line Phase 3 clinical trial of brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, in adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously been treated with an ALK inhibitor.

New EU Lung Cancer Indication for Boehringer's Giotrif

4/7/2016 04:31 pm

(PharmaTimes [UK]) Apr 7, 2016 - The European Commission has widened the license for Boehringer’s non-small cell lung cancer (NSCLC) drug Giotrif, approving it as the first oral treatment option for patients with squamous cell carcinoma of the lung.

Did FDA Remove Scientist’s Name From Article And Invention In Retaliation?

3/28/2016 12:01 pm

(Washington Post/PowerPost) Mar 28, 2016 - Retaliation against workers in federal agencies takes a variety of forms – dismissal and demotion among the most feared. For Dougbeh Chris Nyan, it was denial.

First Injectable Nanoparticle Generator Could Radically Transform Metastatic Breast Cancer Treatment

3/15/2016 11:04 am

(Houston Methodist) Mar 14, 2016 - Landmark preclinical study cured lung metastases in 50 percent of breast cancers by making nanoparticles inside the tumor.

AbbVie Buys Rights To Boehringer Psoriasis Drug For $595 Mln

3/7/2016 06:19 pm

(Yahoo! Finance/Reuters) Mar 7, 2016 - U.S. drugmaker AbbVie has acquired marketing rights to a promising experimental psoriasis treatment from Germany's Boehringer Ingelheim for an initial upfront payment of $595 million.

Boehringer, AbbVie Said to Be in Cancer-Partnership Talks

2/29/2016 01:07 pm

(Bloomberg) Feb 28, 2016 - Boehringer Ingelheim GmbH, the closely held German drugmaker, is in talks with AbbVie Inc. about a significant partnership that could help the companies expand their cancer treatment businesses, people familiar with the discussions said.

UNM Cancer Center Launches Six New Programs, Adds Jobs

2/11/2016 12:00 pm

(Albuquerque Business First) Feb 9, 2016 - The University of New Mexico Comprehensive Cancer Center has lofty plans this year — including hiring at least 18 new doctors and scientists.

Phase 3 Study of BLINCYTO® (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia

2/5/2016 12:04 pm

(Amgen) Feb 4, 2016 - Amgen today announced that the results of a prespecified interim analysis showed that the primary endpoint of improved overall survival was met in the Phase 3 TOWER study.

Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, Receives FDA Breakthrough Therapy Designation In Lung Cancer

12/21/2015 05:49 pm

(Boehringer Ingelheim) Dec 21, 2015 - Boehringer Ingelheim today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for its novel, 3rd-generation, epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI), BI 1482694* (HM61713**).

Sanofi Seeks $25 Billion Deal in Asset Talks With Boehringer

12/15/2015 05:00 pm

(Bloomberg) Dec 15, 2015 - Sanofi is in exclusive talks to swap assets with Germany’s Boehringer Ingelheim GmbH in a 22.8 billion-euro ($25 billion) transaction that would be the largest for the French drugmaker in more than a decade.

Boehringer Ingelheim Canada’s GIOTRIF® (afatinib) Wins Prestigious Prix Galien Canada Innovative Product Award

12/8/2015 05:41 pm

(Biotechnology Focus) Dec 7, 2015 - Boehringer Ingelheim (Canada) Ltd.’s targeted lung cancer treatment, GIOTRIF® (afatinib), has been awarded The Prix Galien Canada – Innovative Product Award.

Boehringer Ingelheim and MD Anderson Join Forces To Discover New Treatment Approaches For Pancreatic Cancer

12/2/2015 05:58 pm

(MD Anderson) Dec 2, 2015 - Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma (PDAC).

Boehringer Ingelheim Initiates Pivotal Programme For Novel Third-Generation EGFR Targeting Lung Cancer Compound

11/3/2015 05:10 pm

(Boehringer Ingelheim) Nov 3, 2015 - First patients enrolled in pivotal Phase II global trial evaluating BI 1482694 (HM61713) in patients with T790M mutation-positive NSCLC.

Boehringer Ingelheim, Eli Lilly Announce FDA Approval of Synjardy as T2D Treatment

8/27/2015 04:59 pm

(StreetInsider) Aug 27, 2015 - The U.S. Food and Drug Administration (FDA) has approved Synjardy (empagliflozin and metformin hydrochloride) tablets, from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company, for the treatment of adults with type 2 diabetes (T2D).

UK Launch for Lilly, Boehringer's Biosimilar Insulin

8/26/2015 05:13 pm

(PharmaTimes [UK]) Aug 26, 2015 - Diabetes patients across the UK can now access Eli Lilly and Boehringer Ingelheim’s biosimilar insulin glargine Abasaglar (previously Abasria) following its launch across the country this week.

FDA and EMA Accept Regulatory Applications for Boehringer Ingelheim's Gilotrif® (afatinib) for Treatment of Advanced Squamous Cell Carcinoma of the Lung

8/26/2015 04:49 pm

(Boehringer Ingelheim) Aug 25, 2015 - Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy.

Lilly, Boehringer Diabetes Drug Cuts Heart Attack, Stroke Risk In Trial

8/20/2015 05:43 pm

(Reuters) Aug 20, 2015 - A new diabetes pill from Eli Lilly and Co and Boehringer Ingelheim cut risk of heart attack, stroke and death in a closely watched study, the first glucose-lowering drug to show such protective results in a large cardiovascular trial, the drugmakers said on Thursday.

Hikma to Buy Boehringer's U.S. Generics Unit For $2.65 Billion

7/28/2015 05:15 pm

(Yahoo! News/Reuters) July 28, 2015 - Hikma Pharmaceuticals Plc said it would buy German drugmaker Boehringer Ingelheim's U.S. specialty generic drugs business for about $2.65 billion in cash and stock to bolster its presence in the United States.

Boehringer Ingelheim Enters Into An Exclusive License Agreement With Hanmi Pharmaceutical To Develop 3rd Generation EGFR Targeted Therapy In Lung Cancer

7/28/2015 05:03 pm

(Boehringer Ingelheim) July 28, 2015 - Boehringer Ingelheim and Hanmi Pharmaceutical Co., Ltd. today announced an exclusive license and collaboration agreement for the development and global commercialization rights, except South Korea, China and Hong Kong, of HM61713, a novel 3rd generation EGFR targeted therapy for the treatment of a specific type of lung cancer.

Boehringer's Giotrif Beats Roche's Tarceva On Lung Cancer Survival

7/6/2015 04:13 pm

(PharmaTimes [UK]) July 6, 2015 - Boehringer Ingelheim’s Giotrif has shown a greater survival benefit than Roche’s Tarceva in previously-treated patients with advanced squamous cell carcinoma of the lung.

Gregory Sutton Joins Tennessee Oncology

7/1/2015 12:02 pm

(The Chattanoogan) July 1, 2015 - Tennessee Oncology announced the arrival of Dr. Gregory Sutton, a medical oncologist who cares for patients at Tennessee Oncology Chattanooga’s Medical Park II location at 2200 East Third St. in Suite 100.

BMS Immunotherapy Accepted For UK Early Access Scheme

6/30/2015 06:05 am

(PharmaTimes [UK]) June 30, 2015 - Patients in the UK with certain forms of lung cancer will be able to access Bristol-Myers Squibb’s immunotherapy Opdivo after the drug was approved by the Medicines and Healthcare products Regulatory Agency for the country’s Early Access to Medicines Scheme.

Melanoma Research Alliance Announces More Than $13 million in New Grants for Melanoma Research

6/24/2015 11:05 am

(MRA) June 23, 2015 – The Melanoma Research Alliance (MRA), the largest private funder of melanoma research, today announced grant awards of more than $13 million to conduct cutting-edge melanoma research.

Applying for the Medicare Oncology Payment Model? Deadline Extended to June 30

6/17/2015 11:05 am

(ASCO in Action) June 16, 2015 - The deadline to apply for the Center for Medicare and Medicaid Innovation's (CMMI) Oncology Care Model (OCM) has been extended to Tuesday, June 30, 2015 at 5 p.m. Eastern Daylight Time.

Penn Study Shows Nearly 10 Percent of Women Live Too Far From Access to Gynecologic Cancer Care

6/11/2015 11:03 am

(Penn Medicine) June 11, 2015 - Findings reveal gaps in specialty care for ovarian, uterine and cervical cancer throughout United States.

Shorter Course of Radiation Has Benefits in Pancreatic Cancer

5/21/2015 12:02 pm

(Medscape Medical News) May 21, 2015 - High-dose, short-term radiation therapy delivered as a 5-day course of stereotactic body radiation therapy (SBRT) may be as effective, or even better, than standard radiotherapy delivered during 6 weeks for the treatment of locally advanced pancreatic cancer (LAPC). The conclusion is based on two recent studies by researchers at Johns Hopkins University, Stanford University, and Memorial Sloan Kettering Cancer Center.

Personalized Approach Helped Cure More Children With Kidney Cancer

5/14/2015 12:05 pm

(Reuters) May 13, 2015 - A personalized treatment targeting a patient's individual genetic makeup helped cure more children with a rare form of kidney cancer, researchers said on Wednesday.

Nancy King Named Regional Director of Cancer Services at Karmanos Cancer Institute in Bay City, Mount Pleasant, West Branch

3/13/2015 11:05 am

( [Bay City, MI]) Mar 13, 2015 - Nancy King has taken on the newly-created position of regional director of cancer services at the Barbara Ann Karmanos Cancer Institute, overseeing operations in Bay City, Mount Pleasant and West Branch.

Pfizer's Lyrica Fails Post-Marketing Study

3/13/2015 11:05 am

(PharmaTimes [UK]) Mar 12, 2015 - Pfizer’s Lyrica (pregabalin) has failed to hit its primary target in a post-marketing study assessing its safety and efficacy in young people with fibromyalgia.

Inherited Gene Variation Leaves Young Leukemia Patients at Risk for Peripheral Neuropathy

2/25/2015 11:04 am

(St. Jude Children's) Feb 24, 2015 - Researchers have identified the first genetic variation that is associated with increased risk and severity of peripheral neuropathy following treatment with a widely used anti-cancer drug.

Doctors' Assumptions on Sex Heighten Lesbians' Cervical Cancer Risk: Study

2/11/2015 11:05 am

(Reuters) Feb 10, 2015 - Lesbians may be at higher risk of cervical cancer because they get fewer screenings than heterosexual women, due partly to doctors' sometimes incorrect assumptions about their sexual history, University of Washington researchers said on Tuesday.

Celsion Submits DNA-based Immunotherapy Clinical Protocol to the FDA as Part of a First Line Treatment for Ovarian Cancer

1/7/2015 11:05 am

(Celsion) Jan 6, 2015 - Lead immunotherapy product candidate GEN-1 to enter dose escalating clinical study in the second half of 2015.

The Burden Of Colon Cancer Shifts From Rich To Poor

11/11/2014 05:05 am

(NPR/Shots blog) Nov 11, 2014 - According to a paper published Monday in the Journal of Clinical Oncology, in the past few decades trends have shifted in those most at-risk to die from colorectal cancer.

Prostate Cancer Could Be 'Switched Off' with Injection

11/11/2014 05:05 am

(The Telegraph [UK]) Nov 10, 2014 - Prostate cancer could be ‘switched off’ after scientists discovered a way to prevent deadly tumours from spreading. Bristol and Nottingham universities found that a single molecule plays a crucial role in the forming of new blood vessels.

Positive Phase 3 Data For Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated With Yervoy (ipilimumab) Presented at the ESMO 2014 Congress; First Phase 3 Results Presented For a PD-1 Immune Checkpoint Inhibitor

9/30/2014 07:03 am

(BMS) Sept 29, 2014 - Bristol-Myers Squibb Company today announced positive results from CheckMate -037, a Phase 3 randomized, controlled open-label study of Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma who were previously treated with Yervoy (ipilimumab).